Boston Scientific has gained European approval for the fully covered WallFlex stent to treat refractory benign esophageal strictures. Benign esophageal strictures, caused by scar tissue that narrows the esophagus, are conventionally treated by dilating the esophagus over periodic intervals. Unlike conventional dilation treatment, the WallFlex stent makes use of a braided nitinol structure to keep the esophagus open in the presence of strictures.
The stent is fully covered with Permalume silicone coating that prevents tumor ingrowth as well as food impaction. The WallFlex stent construction also has a progressive step flared end design to prevent stent migration and allows for improved stent anchoring to the esophagus. The stent is designed to expand fully over a period of 24 to 72 hours after implantation and features a Teflon coated removal suture that allows for stent repositioning or removal. The stent is delivered using a 18.5 Fr. delivery system that is designed to travel across narrow strictures.
The fully covered WallFlex stent has previously received CE Mark and FDA approval for the alternate indication of palliative treatment of malignant esophageal strictures.
Product page: Fully Covered Wall Flex Stent…